Asset Details
Do you wish to reserve the book?
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
Do you wish to request the book?
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
2025
Overview
In this trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms.
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Agents, Hormonal - adverse effects
/ Antineoplastic Agents, Hormonal - pharmacokinetics
/ Aromatase Inhibitors - adverse effects
/ Aromatase Inhibitors - pharmacokinetics
/ Breast Neoplasms - drug therapy
/ Diaries
/ Female
/ Hot Flashes - chemically induced
/ Humans
/ Neurokinin-1 Receptor Antagonists - administration & dosage
/ Neurokinin-1 Receptor Antagonists - adverse effects
/ Neurokinin-1 Receptor Antagonists - pharmacokinetics
/ Oncology
/ Placebos
/ Receptors, Neurokinin-3 - antagonists & inhibitors
/ Tamoxifen - pharmacokinetics
